Neonatal Sepsis Episodes and Retinopathy of Prematurity in Very Preterm Infants.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Jul 2024
Historique:
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: epublish

Résumé

Retinopathy of prematurity (ROP) is a major morbidity of preterm infants causing visual impairment, including blindness, for which timely treatment is vital and prevention is key. Increasing evidence suggests that exposure to neonatal sepsis contributes to ROP development. To investigate the association between neonatal sepsis and ROP in 2 large-scale cohorts of preterm infants born at less than 29 weeks' gestation. This retrospective cohort study was conducted using data from the German Neonatal Network (GNN) and Norwegian Neonatal Network (NNN). The GNN involves 68 and the NNN includes 21 level III neonatal intensive care units. Participants were infants born at a gestation of 22 weeks and 0 days to 28 weeks and 6 days and enrolled in the GNN between January 1, 2009, and December 31, 2022, and NNN between January 1, 2009, and December 31, 2018. Data were analyzed from February through September 2023. Single or multiple episodes of culture-proven sepsis. Any ROP and treatment-warranted ROP. Among 12 794 infants in the GNN (6043 female [47.2%] and 6751 male [52.8%]; mean [SD] gestational age, 26.4 [1.5] weeks) and 1844 infants in the NNN (866 female [47.0%] and 978 male [53.0%]; mean [SD] gestational age, 25.6 [1.5] weeks), the mean (SD) birth weight was 848 (229) g and 807 (215) g, respectively. Any ROP was present in 6370 infants (49.8%) in GNN and 620 infants (33.6%) in NNN, and treatment-warranted ROP was present in 840 infants (6.6%) in GNN and 140 infants (7.6%) in NNN. In both cohorts, there were increasing rates of treatment-warranted ROP with each sepsis episode (no sepsis: 572 of 10 658 infants [5.4%] in GNN and 85 of 1492 infants (5.7%) in NNN; 1 episode: 190 of 1738 infants in GNN [10.9%] and 29 of 293 infants [9.9%] in NNN; 2 episodes: 53 of 314 infants in GNN [16.9%] and 13 of 49 infants [26.5%] in NNN; 3 episodes: 25 of 84 infants [29.8%] in GNN and 3 of 10 infants [30.0%] in NNN). After adjusting for multiple confounders in the GNN dataset, the number of sepsis episodes was associated with ROP and treatment-warranted ROP compared with 0 episodes (1 episode: adjusted odds ratio [aOR], 1.44 [95% CI, 1.27-1.63]; P < .001 and OR, 1.60 [95% CI, 1.31-1.96]; P < .001, respectively; 2 episodes: OR, 1.81 [95% CI, 1.35-2.42]; P < .001 and OR, 2.38 [95% CI, 1.68-3.37]; P < .001, respectively; 3 episodes: OR, 4.39 [95% CI, 2.19-8.78]; P < .001 and OR, 3.88 [95% CI, 2.29-6.55]; P < .001, respectively). These associations were confirmed for any ROP by propensity score matching (for example, the aOR with propensity score matching was 1.76 [95% CI, 1.54-2.02]; P < .001 for 1 episode vs 0 episodes and 1.58 [95% CI, 1.12-2.22]; P = .007 for 3 episodes vs 0 or 1 episode). In the NNN dataset, surgical NEC was associated with treatment-warranted ROP (multivariable analysis: aOR, 3.37 [95% CI, 1.78-6.37]; P < .001). This study found that in the large-scale GNN cohort, recurrent culture-proven sepsis was associated with ROP and treatment-warranted ROP in infants born at less than 29 weeks.

Identifiants

pubmed: 39052290
pii: 2821486
doi: 10.1001/jamanetworkopen.2024.23933
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2423933

Investigateurs

Kirstin Faust (K)
Dirk Müller (D)
Ulrich Thome (U)
Florian Guthmann (F)
Axel von der Wense (A)
Christian Wieg (C)
Ursula Weller (U)
Thomas Höhn (T)
Dirk Olbertz (D)
Ursula Felderhoff-Müser (U)
Rainer Rossi (R)
Norbert Teig (N)
Friedhelm Heitmann (F)
Matthias Heckmann (M)
Susanne Schmidtke (S)
Bettina Bohnhorst (B)
Angela Kribs (A)
Matthias Vochem (M)
Sven Wellmann (S)
Jens Möller (J)
Joachim Eichhorn (J)
Jürgen Wintgens (J)
Ralf Böttger (R)
Markus Flügel (M)
Mechthild Hubert (M)
Michael Dördelmann (M)
Georg Hillebrand (G)
Claudia Roll (C)
Reinhard Jensen (R)
Mario Rüdiger (M)
Alexander Humberg (A)
Ann Carolin Longardt (AC)
Stefan Schäfer (S)
Thomas Schaible (T)
Axel Franz (A)
Kay Hensel (K)
Steffen Kunzmann (S)
Esther Schmidt (E)
Thorsten Orlikowsky (T)
Hubert Gerleve (H)
Nico Depping (N)
Roland Haase (R)
Marc Hoppenz (M)
Daniel Vilser (D)
Helmut Küster (H)
Hans Fuchs (H)
Thorsten Körner (T)
Thomas Brune (T)
Andreas Müller (A)
Florian Urlichs (F)
Martin Berghäuser (M)
Hans Proquitté (H)
Patrick Morhart (P)
Wolfgang Lindner (W)
Rolf Schlösser (R)
Welfhard Schneider (W)
Michael Schroth (M)
Esther Rieger-Fackeldey (E)
Frank Dohle (F)
Jaqueline Bauer (J)
Thomas Völkl (T)
Francisco Brevis Nunez (F)
Michael Welsch (M)
Marcus Krüger (M)

Auteurs

Kirsten Glaser (K)

Division of Neonatology, Department of Women's and Children's Health, University of Leipzig Medical Center, Leipzig, Germany.

Christoph Härtel (C)

Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.

Claus Klingenberg (C)

Paediatric Research Group, Faculty of Health Sciences, University of Tromsø-Arctic University of Norway, Tromsø, Norway.
Department of Pediatrics and Adolescence Medicine, University Hospital of North Norway, Tromsø, Norway.

Egbert Herting (E)

Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Mats I Fortmann (MI)

Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Christian P Speer (CP)

Department of Pediatrics, University Hospital of Würzburg, Würzburg, Germany.

Hans J Stensvold (HJ)

Department of Neonatal Intensive Care, Clinic of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Zuzana Huncikova (Z)

Paediatric Department, Stavanger University Hospital, Stavanger, Norway.
Department of Clinical Science, University of Bergen, Bergen, Norway.

Arild E Rønnestad (AE)

Department of Neonatal Intensive Care, Clinic of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Medical Faculty, Institute for Clinical Medicine, University of Oslo, Oslo.

Martin M Nentwich (MM)

Department of Ophthalmology, University Hospital of Würzburg, Würzburg, Germany.

Andreas Stahl (A)

Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany.

Olaf Dammann (O)

Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts.
Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.
Department of Neuromedicine and Movement Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Wolfgang Göpel (W)

Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH